Objective: In this study, we aim to evaluate trends in the condition of fetuses and neonates with hemolytic disease at the time of first intrauterine transfusion (IUT) and at birth, in relation to routine first-trimester antibody screening, referral guidelines, and centralization of fetal therapy.
In the first 3 years after the introduction of intravascular IUT in the Netherlands (1987) (1988) (1989) , the majority of cases (55%) presented with hydrops. 5 A recent study from our group showed that the incidence of fetal alloimmune hydrops has declined to approximately 13%. 6 In this study, we aimed to evaluate trends in the condition of fetuses and newborns with hemolytic disease at the time of first IUT and at birth and discuss possible contributing factors.
2 | METHODS
| Study design, setting, and study population
We conducted a retrospective cohort study including all patients with . 7 The prevalence of a clinically relevant alloantibody (father positive for the antigen) at first-trimester screening was 0.14% to 0.33% in 2016. 8 Patient data, IUT details, and information on pregnancy outcome of these patients were collected from our electronic prospectively filled Rhesus database. Cases were excluded if fetal or neonatal death occurred from causes other than red cell immunization. Diagnostic fetal blood samplings not followed by IUT, owing to adequate pretransfusion fetal hemoglobin, were excluded. If the diagnostic fetal blood sampling confirmed fetal anemia, but the following transfusion failed due to technical difficulties or complications, the procedure was not excluded.
Suspected severe fetal anemia requiring IUT was defined as (1) a peak systolic velocity in the fetal middle cerebral artery (MCA) of 1.5 multiples of the median for gestational age, detected by Doppler measurement, and/or (2) the presence of other signs of anemia at ultrasound examination (cardiomegaly, ascites, hydrops), or (3) amniotic fluid delta optical density measurements reaching the upper part of the Liley zone II or zone III (only in the early years of this study). To prevent non-D immunizations, blood transfusions administered to women of reproductive age (<45 y) are K-(since 2004), c-, and E-matched in the Netherlands (since 2011). 10 The order of implementation of these and other preventive measures for red cell immunization in the Netherlands is summarized in Table S1 . Institute for Blood Group Investigation in Groningen, the two national referral laboratories.
| Prevention, screening, diagnostics, and treatment

11,12
In case of a high risk of severe hemolysis, indicated by serological testing or abnormal ultrasound findings, national obstetric guidelines advise the patient to be referred to the LUMC. The current screening and prevention protocol in the Netherlands is summarized in a recent review of de Haas et al and in a national obstetric guideline. 1, 12 Patients with D antibodies are to be referred to the LUMC when titers grossly rise above 1:16 or when the ADCC is higher than 50% (>1:16 and >30% for other Rh antibodies and 1:2 and 30% for anti-K). The management of pregnancies complicated by HDFN in our center consists of weekly monitoring with MCA Doppler until anemia is suspected and intervention is needed, and information is described in more detail previously. What's already known about this topic?
• Severe alloimmune hydrops is associated with impaired outcome on both the short term and the long term.
What does this study add?
• With routine early alloantibody screening, national guidelines, and pooling of expertise in national reference laboratories and a referral center for fetal therapy, severe alloimmune hydrops has almost disappeared.
• Survival of hydrops cases no longer differs from hemolytic disease of the fetus and newborn cases without hydrops.
• Children treated with intrauterine transfusions are now in better condition at birth.
Hydrops was classified as mild, if a distinct rim of ascites in the absence or presence of pericardial effusion was seen, whereas abundant ascites, in the absence or presence of pericardial and pleural effusion and skin edema, was considered as severe hydrops. Perinatal survival in consecutive time cohorts was assessed for all fetuses and for those with or without alloimmune hydrops.
| Ethical considerations
Only the caregivers knew the identity of their patients, and study data were analyzed anonymously. Therefore, the medical ethics committee of the LUMC approved this research (C15.094) and decided, according to the Medical Research Involving Human Subjects Act (WMO), that written informed consent was not needed.
| Statistical analysis
As outcome of multiple pregnancies in the same woman might be interrelated, outcomes were compared using generalized estimating equations (GEE). Within the GEE, a linear, binary logistic or ordinal logistic model was used for comparison of estimated means or odds, respectively. "Time cohort" was used as a continuous predictor to assess a linear trend in variables over time, rather than an overall difference in the variable between all time groups.
Before the use of MCA Doppler became the gold standard to set the indication for IUT around 2000, amniotic fluid delta optical density measurements were used. These are now known to be less accurate in predicting moderate to severe anemia, 15 and therefore, a sensitivity analysis was performed for our main outcome analysis, with only patients treated from 2000 onwards.
Numerical outcomes that were not normally distributed were transformed to normality (log2 transformation for titers, gestational age at birth raised to the power of 10).
If important outcomes showed a significant trend over time, we assessed possible factors associated with this outcome by multivariate regression using backward selection (Table S2 ). The choice for inclusion of variables was made on theoretical grounds, and a P value of >0.1 was used for exclusion of variables.
P values < 0.05 were considered statistically significant.
3 | RESULTS
| Characteristics of the study population
During the 30-year study period, IUTs were started in 653 fetuses in 645 pregnancies of 551 women. There were eight twin pregnancies in which both twins were treated with IUT and one more in which only one fetus required IUTs; the cotwin was D-negative. Six singleton pregnancies were excluded because fetal death occurred from causes other than red cell alloimmunization, described in more detail previously. 16 Two more cases were excluded, as fetal blood sampling did not reveal fetal anemia, and therefore, no transfusion was performed.
A total of 645 fetuses remained for analysis in 637 pregnancies of 543 women, receiving a total of 1852 transfusions. In the first time cohort, fetuses received a median of 4 (range 1-8) transfusions per pregnancy, declining to 3 (range 1-6) in the last time cohort (P = 0.003); 55% of fetuses treated with IUT were male, and 45%
female. Table 1 shows overall baseline characteristics of these pregnancies and trends in characteristics over time. Other includes E, e, Fya, Jka, and very infrequent antibodies.
d Overall GA over time.
| Trends in fetal condition at first transfusion over time
All primary and secondary outcomes are shown in Table 2 
| Trends in survival and neonatal condition over time
Trends in survival of hydropic and nonhydropic fetuses are shown in Figure 2 and Table 2 (23) 38 (41) 47 (37) 40 (25) 18 (12) 7 (6) 0.556 (0.48-0.65)
<0.001
Mild 93 (14) 18 (20) 28 (22) 28 (18) 13 (9) 6 (5) 0.690 (0.59-0.81)
Severe 57 (9) 20 (22) 19 (15) 12 (8) 5 (3) 1 (1) (4) 8 (10) 5 (4) 7 (4) 1 (1) 2 (2) 0.572 (0.39-0.83) 0.004
Neonates requiring exchange transfusion(s) b 298 (51) 68 (91) 76 (64) 94 (64) 42 (29) 18 (17) 0.420 (0.36-0.49) <0.001
Hb at birth, g/dL 11.3 ± 2. 
| DISCUSSION
This 30-year cohort study describes factors that contribute to the gradual and near disappearance of severe alloimmune hydrops, a serious condition that has negatively influenced fetal survival and longterm outcome for decades. The hydrops rate at first IUT keeps declining since the introduction of routine first-trimester antibody screening in 1998. In the last years of this study, less than 1% (1/115) of fetuses suffered from severe hydrops. Survival of fetuses with and without hydrops is nowadays almost equal, rising up to or above 95%. Furthermore, fetuses are nowadays born less anemic, which was associated with additional intraperitoneal transfusion at the last IUT.
Since the introduction of early screening of all pregnant women in the Netherlands in 1998, the overall hydrops rate in fetuses requiring IUT declined from 39% to 15%, and the incidence of severe hydrops reduced more than fourfold, from 18% to 4%. This impressive currently low incidence of fetal hydrops indicates that fetuses with HDFN are nowadays identified and treated more timely. We hypothesize that this is mainly due to the implementation of national guidelines on management of alloimmunization in pregnancy, covering screening, laboratory, and clinical monitoring and protocols for timely referral to the (single) fetal therapy center. The hydrops rates we found are comparable with those reported in other Western countries with similar screening programs, which vary between 8% and 16%. [17] [18] [19] [20] [21] [22] [23] A study from Belgium also reported severe hydrops in 5% of red cell-immunized pregnancies. In developing countries, where routine early antibody screening is less well organized or lacking, 24 the incidence of hydrops at time of first IUT is remarkably higher. A group from Brazil reported a 34%
hydrops rate in their cohort with mainly D-immunized pregnancies, which they contributed to late referral. 25 In the largest tertiary referral center in India, the hydrops rate was 22% in patients with D immunization requiring IUT between 2011 and 2014. Equal to our findings, survival was approximately the same for hydropic and nonhydropic fetuses in this cohort (94% vs. 90%, respectively). 26 An additional explanation for the declining incidence of hydrops is the optimization of diagnostic accuracy to predict severe fetal anemia over time. The previously used amniotic fluid delta optical density measurements 27 showed limited accuracy in the second pregnancy trimester and in K-immunized pregnancies 15, 28 and were gradually replaced by measuring the peak flow velocity in the MCA by Doppler ultrasound, which is standard diagnostic care since around 2000. 29 To account for this change in diagnostic management, we performed a sensitivity analysis with only cases included from 2000 onwards. This analysis showed a similar result to the main analysis: OR for the presence of hydrops in a later time cohort 0.459, P < 0.001.
An important finding is that survival of fetuses with hydrops increased significantly, leading to a similar survival rate in hydropic and nonhydropic fetuses in recent years. This confirms findings by others 23, 26 and is likely partly due to early detection and timely referral for treatment of fetal anemia. Thus, hydrops, if it occurs at all, is nowadays usually only mild, which is associated with favorable outcome. Furthermore, the increase in survival is most profound in cases with severe hydrops (OR 3.3). A more advanced gestational age at The lightest grey is the total cohort, the darker grey is the fetuses without hydrops, and the darkest line reflect fetuses with mild or severe hydrops at time of first intrauterine transfusion birth in later years of the study and/or advancements in prenatal and especially neonatal management in the past decades may have contributed, as well as a decrease in IUT complications. 6 Centralization of fetal therapy and neonatal care in large volume centers is increasingly important for quality of care. 30 Infants born alive after treatment with IUT(s) seem to be in better neonatal condition nowadays, being less anemic at birth (despite longer intervals between the last transfusion and birth) and needing less exchange transfusions. We found that both additional intraperitoneal transfusion, in adjunct to intravascular transfusion, and more advanced gestational age at birth were independently associated with higher neonatal hemoglobin. As we previously demonstrated, transfusions through the intrahepatic route gained popularity over the years and are associated with less procedure-related complications. 6 An additional advantage of this transfusion technique is the possibility to deposit some extra blood intraperitoneally with the aim to prolong the interval between transfusions or between the last transfusion and birth. 31 We hypothesize that the found reduction in need for exchange transfusions is mainly caused by the gradual replacement of this invasive procedure by high-quality intensive phototherapy and the corresponding more restrictive exchange transfusion protocol in 2004. 32 This study is conducted in a well-organized health care system for alloimmunized pregnant women. The centralization of screening and treatment gives us great insight and overview in the prevalence of alloimmunization and the details of intrauterine therapy. A limitation might be that we were not able to include fetuses with hydrops, but without IUT. It is therefore possible that some women lost their fetuses to severe hydrops before referral to our national referral center or that labor was induced before performing an IUT. We hypothesize that the subsequent underestimation of hydrops deaths will be greatest in the early years of the study, as this scenario is highly unlikely in the present screening setting.
| CONCLUSION
In summary, the incidence of alloimmune fetal hydrops has decreased importantly over the past decades, most likely as a result of the introduction of early screening for alloantibodies in all pregnancies, use of national guidelines, and the availability of both national reference laboratories and the pooling of knowledge and expertise in a referral center for fetal therapy. In particular, severe alloimmune hydrops, a formerly often lethal condition, has practically disappeared, not only leading to improved survival of HDFN but also diminishing risk of long-term impairment.
